DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for synovial plica syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSynovial plica syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for synovial plica syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT) — HGSNAT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8JL3 · 2.59 Å · ligand ACETYL COENZYME *A (ACO). Experimental structure, not a prediction.
What the evidence adds up to
Synovial plica syndrome occurs when a normal embryonic remnant in the knee becomes painful after injury or overuse, presenting as anterior knee pain that can be difficult to diagnose. The suprapatellar plica is the most common type but is usually asymptomatic; in 3 to 30% of cases plicae become symptomatic. One case report describes a patient with spontaneous knee pain and swelling caused by an atraumatic hematoma trapped in the suprapatellar bursa by a complete suprapatellar plica, a presentation the authors state has not been described before.
A 2024 case report describes an avid runner whose synovial plica syndrome pain was refractory to arthroscopic plica excision, physical therapy, nonsteroidal anti-inflammatory drugs, and intraarticular steroid injections. He received three rounds of lumbar sympathetic block, which resulted in significant and sustained pain relief. The authors suggest this indicates a sympathetic component to the condition. This is a single case, not a controlled trial.
No controlled trials of lumbar sympathetic block for synovial plica syndrome exist. The evidence for any treatment remains limited to case reports and reviews. What is missing is prospective, controlled studies with adequate sample sizes, standardised diagnostic criteria, and clear outcome measures that distinguish which patients might benefit from sympathetic blockade versus other interventions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Surgery Journal · 2017 · 58 citations · open access
Synovial Plica Syndrome of the Knee: A Commonly Overlooked Cause of Anterior Knee Pain
AbstractSynovial plica syndrome (SPS) occurs in the knee, when an otherwise normal structure becomes a source of pain due to injury or overuse. Patients may present to general practitioners, physiotherapists, or surgeons with anterior knee pain with or without mechanical symptoms, and the diagnosis can sometimes be difficult. Several studies have examined the epidemiology, diagnosis, and treatment of SPS. We review these resources to provide an evidence-based guide to the diagnosis and treatment of SPS of the knee.
Lumbar Sympathetic Block for Treatment of Knee Pain From Synovial Plica Syndrome: A Case Report
AbstractLumbar sympathetic blocks (LSBs) are used to treat sympathetically mediated pain in the lower extremities, kidneys, ureters, and genitals. LSBs use local anesthetic to block the sympathetic system to modulate pain response. In this case report, an avid runner was diagnosed with synovial plica syndrome. His pain was refractory to arthroscopic plica excision, physical therapy, nonsteroidal anti-inflammatory drugs, and intraarticular steroid injections. He received 3 rounds of LSB resulting in significant and sustained pain relief. This case suggests that LSB successfully treated knee pain from synovial plica syndrome and there may be a sympathetic component to this disease state.
International Journal of Case Reports in Orthopaedics · 2024 · 0 citations · open access
Undercover hematoma: A rare presentation of a complete suprapatellar plica
AbstractSynovial plicae are remnants of synovial septa that fail to fully resorb during embryonic knee development. In 3 to 30% of cases, they can become symptomatic (synovial plica syndrome), typically presenting with anterior knee pain exacerbated by knee flexion. Plicae are classified based on their location, with the suprapatellar being the most common but typically asymptomatic.This article describes a clinical case of spontaneous knee pain and swelling revealed to be secondary to an atraumatic hematoma confined to the suprapatellar bursa by the presence of a complete suprapatellar synovial plica. According to the authors' research, there are no described cases with a similar presentation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
